title: Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.
abstract: OBJECTIVE
  • To evaluate the cytotoxicity of dimeric naphthoquinones (BiQs) in prostate cancer cells. • To assess the interaction of dimeric naphthoquinones with common therapies including radiation and docetaxel.
  
  
  METHODS
  • The cytotoxicity of 12 different dimeric naphthoquinones was assessed in androgen-independent (PC-3, DU-145) and androgen-responsive (LNCaP, 22RV1) prostate cancer cell lines and in prostate epithelial cells (PrECs). • BiQ2 and BiQ11 were selected for determination of dose response, effects on colony formation and initial exploration into mechanism of action. • Synergistic effects with radiation and docetaxel were explored using colony-forming and MTT assays.
  
  
  RESULTS
  • At concentrations of 15µM, BiQ2, BiQ3, BiQ11, BiQ12, and BiQ15 demonstrated cytotoxicity in all prostate cancer cell lines. • Treatment with BiQs limited the ability of prostate cancer cells to form colonies in clonogenic assays. • Exposure of prostate cancer to BiQs increased cellular reactive oxygen species (ROS), decreased ATP production, and promoted apoptosis. • BiQ cytotoxicity was independent of NADP(H):quinone oxidoreductase 1 (NQO1) activity in PrECs, PC-3 and 22RV1, but not DU-145 cells. • Exposure of prostate cancer cells to radiation before treatment with BiQs increased their activity allowing for inhibitory effects well below the IC(50) s of these compounds in PrECs. • Co-administration of BiQs with docetaxel had minimal additive effects.
  
  
  CONCLUSIONS
  • Dimeric naphthoquinones represent a new class of compounds with prostate cancer cytotoxicity and synergistic effects with radiation. The cytotoxic effect of these agents is probably contributed to by the accumulation of ROS and mitochondrial dysfunction. • Further studies are warranted to better characterize this class of potential chemo-therapeutics.
authors.affiliation: Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
authors.forename: Ashley E
authors.initials: AE
authors.lastname: Ross
authors.forename: Ashkan
authors.initials: A
authors.lastname: Emadi
authors.forename: Luigi
authors.initials: L
authors.lastname: Marchionni
authors.forename: Paula J
authors.initials: PJ
authors.lastname: Hurley
authors.forename: Brian W
authors.initials: BW
authors.lastname: Simons
authors.forename: Edward M
authors.initials: EM
authors.lastname: Schaeffer
authors.forename: Milena
authors.initials: M
authors.lastname: Vuica-Ross
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000528:radiation effects; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000737:chemistry / Q000494:pharmacology* / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011839:Radiation, Ionizing; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D009285:Naphthoquinones; D017382:Reactive Oxygen Species; D000255:Adenosine Triphosphate